---
layout: post
title: "INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman &amp; Dowd LLP Announces - RARE"
date: 2026-02-19T17:20:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/investor-deadline-ultragenyx-pharmaceutical-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-robbins-geller-rudman--dowd-llp-announces---rare-302692453.html
significance: 9.00
---

<p>SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the "Class Period"), have until April 6, 2026 to...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/investor-deadline-ultragenyx-pharmaceutical-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-robbins-geller-rudman--dowd-llp-announces---rare-302692453.html)

**Published:** 2026-02-19 17:20:00 +0000

**Significance Score:** 9.00

[View original](https://www.prnewswire.com/news-releases/investor-deadline-ultragenyx-pharmaceutical-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-robbins-geller-rudman--dowd-llp-announces---rare-302692453.html)
